Cancer Stem Cell Subpopulations Are Present Within Metastatic Head and Neck Cutaneous Squamous Cell Carcinoma

Ethan J. Kilmister 1, Josie Patel 1, Bede van Schaijik 1, Nicholas Bockett 1, Helen D. Brasch 1, Erin Paterson 1, Dalice Sim 2, Paul F. Davis 1, Imogen M. Roth 1, Tinte Itinteang 1 and Swee T. Tan 1,3,4*

1 Gillies McIndoe Research Institute, Wellington, New Zealand. 2 Biostatistical Group/Dean’s Department, University of Otago, Wellington, New Zealand. 3 Wellington Regional Plastic, Maxillofacial and Burns Unit, Hutt Hospital, Wellington, New Zealand. 4 Department of Surgery, The University of Melbourne, Parkville, VIC, Australia

Cancer stem cells (CSCs) have been identified in many cancer types including primary head and neck cutaneous squamous cell carcinoma (HNcSCC). This study aimed to identify and characterize CSCs in metastatic HNcSCC (mHNcSCC). Immunohistochemical staining performed on mHNcSCC samples from 15 patients demonstrated expression of the induced pluripotent stem cell (iPSC) markers OCT4, SOX2, NANOG, KLF4, and c-MYC in all 15 samples. In situ hybridization and RT-qPCR performed on four of these mHNcSCC tissue samples confirmed transcript expression of all five iPSC markers. Immunofluorescence staining performed on three of these mHNcSCC samples demonstrated expression of c-MYC on cells within the tumor nests (TNs) and the peri-tumoral stroma (PTS) that also expressed KLF4. OCT4 was expressed on the SOX2+/NANOG+/KLF4+ cells within the TNs, and the SOX2+/NANOG+/KLF4+ cells within the PTS. RT-qPCR demonstrated transcript expression of all five iPSC markers in all three mHNcSCC-derived primary cell lines, except for SOX2 in one cell line. Western blotting showed the presence of SOX2, KLF4, and c-MYC but not OCT4 and NANOG in the three mHNcSCC-derived primary cell lines. All three cell lines formed tumorspheres, at the first passage. We demonstrated an OCT4+/NANOG+/SOX2+/KLF4+/c-MYC+ CSC subpopulation and an OCT4+/NANOG-/SOX2+/KLF4+/c-MYC+ subpopulation within the TNs, and an OCT4+/NANOG+/SOX2+/KLF4+/c-MYC+ subpopulation within the PTS of mHNcSCC.

Keywords: metastatic cutaneous squamous cell carcinoma, cancer stem cells, induced pluripotent stem cells, embryonic stem cells, head and neck cancer, nodal metastasis

INTRODUCTION

The incidence of non-melanoma skin cancer (NMSC) is rising rapidly globally, particularly amongst Anglo-Celtic populations (1). Cutaneous squamous cell carcinoma (cSCC) is the second most common form of NMSC, affecting 118/100,000 people in New Zealand (1). Caucasian descent, pale complexion and advancing age increase the risk of developing cSCC (2). Tumor thickness,
horizontal diameter, perineural and/or lymphovascular invasion, poor histological differentiation and certain anatomic sites increase the metastatic risk (1, 3–5).

Sixty percent of cSCC occur in the head and neck with a 2% incidence of metastasis, mainly to the parotid and/or neck nodes (4), making metastatic cSCC the most common parotid malignancy in New Zealand and Australia (6). Treatment for metastatic head and neck cSCC (mHNcSCC) is surgery and post-operative adjuvant radiotherapy with a 48% 5-year overall survival (2). This poor outcome has been attributed to the presence of cancer stem cells (CSCs) (7).

The CSC concept proposes that the development and progression of cancer are driven by CSCs (8), a small population of highly tumorigenic cells imbued with embryonic stem cell (ESC) properties (9), such as self-renewal (10), and pluripotency (9). CSCs divide asymmetrically to produce identical CSCs, as well as differentiated cancer cells that possess little or no tumorigenicity and form the bulk of the tumor (11, 12).

Yamanaka et al. (13, 14) have demonstrated induction of pluripotent stem cells from adult mouse and human fibroblasts by the introduction of the ESC markers OCT4, SOX2, c-MYC, and KLF4. Thomson et al. (15) have demonstrated that this can also be achieved with NANOG and LIN28 in place of c-MYC and KLF4. These studies underscore the sufficiency of these four transcription factors (13) to generate induced pluripotent stem cells (iPSCs). CSCs in several cancer types (16–18) including primary head and neck cSCC (HNcSCC) (19) have been shown to express these master regulators of pluripotency.

SOX2, a member of the SRY-related HMG-box (SOX) gene family of transcription factors that maintains developmental potential (20), is a marker of CSCs in cSCC (21). SOX2 expression is critical for tumor initiation and growth, and regulates self-renewal and long-term growth of CSCs (21–23). OCT4, a POU domain transcription factor (24), forms the “core pluripotency network” with SOX2 and NANOG to regulate ESC pluripotency (25) and stemness of CSCs in HNcSCC (26). Its expression correlates with poor overall survival of patients with oral cavity SCC (OCSCC) (27). NANOG, a homeodomain containing transcription factor (28), also correlates with worsened survival of OCSCC (27). NANOG induces CSC characteristics in OCSCC (27) and colorectal cancer (29). KLF4, a zinc-finger transcription factor and part of the Krüppel-like family, plays a central role in cell cycle regulation, maintenance of pluripotency and somatic cell reprogramming (30). c-MYC, an oncprotein within the MYC family, is involved in cell growth, differentiation, apoptosis, angiogenesis, and stem cell pluripotency and proliferation (31, 32). MYC dysregulation occurs in various cancer types (33–35) and is associated with more aggressive tumors (36).

OCT4, SOX2, NANOG, KLF4, and c-MYC act cooperatively to promote pluripotency (37), and consequently, some or all of these markers have been used to identify CSC subpopulations in many cancer types, including HNcSCC (19), OCSCC affecting different subsites (38–40), glioblastoma (41), renal clear cell carcinoma (17), primary (18), and metastatic (42) colon adenocarcinoma, and metastatic malignant melanoma (43, 44).

We have recently demonstrated the presence of CSCs in primary HNcSCC that express the iPSC markers OCT4, SOX2, NANOG, KLF4, and c-MYC (19). This study aimed to identify and characterize CSCs within mHNcSCC using these markers.

### MATERIALS AND METHODS

#### mHNcSCC Tissue Samples

Formalin-fixed paraffin-embedded (FFPE) sections of mHNcSCC tissue samples from 15 male patients, aged 53–92 (mean, 80 years) (Table 1) were sourced from the Gillies McIndoe Research Institute Tissue Bank for this study, which was approved by the Central Regional Health and Disability Ethics Committee (Ref. 12/CEN/74AM05). The mHNcSCC tissue samples used were from a separate cohort of patients than those used in our previous study that investigated CSCs in primary HNcSCC (19). Written informed consent was obtained from all patients.

#### mHNcSCC-Derived Primary Cell Lines

mHNcSCC-derived primary cell lines were established from three freshly excised mHNcSCC tissue samples from the 15 patients included in the IHC staining, and cultured as explants by placing them between layers of Matrigel (cat#354234, Corning Life Sciences, Tewksbury, MA, USA) in 24-well plates and adding an explant culture media DMEM (cat#10569010, Gibco, Rockford, IL, USA) + 2% penicillin-streptomycin (cat#15140122, Gibco) + 0.2% gentamycin/amphotericin B (cat#R01510, Gibco). Cells were extracted from the Matrigel following abundant growth using Dispase (cat#354235, Corning Life Sciences). The extracted cells were cultured and passaged in a cell culture media consisting of DMEM (1X) (Gibco) and GlutaMAX-1 (cat#10569-010, Life Technologies), DMEM medium supplemented with 10% fetal bovine serum (cat#10091148, Gibco), 5% mTeSR™ (cat#85850, StemCell Technologies, Vancouver, BC, Canada), 1% penicillin-streptomycin (Gibco) and 0.2% gentamicin/amphotericin B (Gibco). All cultures were grown in 5% CO₂, 37°C, 7.5% humidity.

#### Patient demographics and site of nodal metastasis of metastatic cutaneous head and neck squamous cell carcinoma.

| Patient | Gender | Age (years) | Site of nodal metastasis |
|---------|--------|------------|--------------------------|
| 1       | M      | 69         | Neck                     |
| 2       | M      | 84         | Parotid and neck         |
| 3       | M      | 92         | Parotid                  |
| 4       | M      | 90         | Parotid                  |
| 5       | M      | 89         | Parotid and neck         |
| 6       | M      | 83         | Parotid                  |
| 7       | M      | 89         | Neck                     |
| 8       | M      | 82         | Parotid and neck         |
| 9       | M      | 53         | Neck                     |
| 10      | M      | 74         | Parotid and neck         |
| 11      | M      | 74         | Neck                     |
| 12      | M      | 85         | Neck                     |
| 13      | M      | 78         | Parotid                  |
| 14      | M      | 85         | Neck                     |
| 15      | M      | 78         | Parotid and neck         |
maintained in a humidified incubator at 37°C with 5% CO₂. All mHNcSCC-derived primary cell lines used for the experiments were at passages 4–8 (WB and RT-qPCR) or 7–9 (tumorsphere formation assays).

**Histochemical, Immunohistochemical, and Immunofluorescence Staining**

Four micro meter-thick FFPE consecutive sections of mHNcSCC tissue samples from 15 patients underwent hematoxylin and eosin (H&E) staining to confirm the presence of mHNcSCC on the slides by an anatomical pathologist, and immunohistochemical IHC staining with the primary antibodies OCT4 (1:30; cat#MRQ-10, Cell Marque), SOX2 (1:500; cat#PA1-094, Thermo Fisher Scientific), NANOG (1:200; cat#EP225, Cell Marque), KLF4 (1:100; cat#NBP2-24749, Novus Biologicals), c-MYC (1:1000; cat#ab32, Abcam, Cambridge, MA, USA), and KLF4 (1:100; cat#NBP2-24749, Novus Biologicals, Littleton, CO, USA), with 3,3′-diaminobenzidine as the chromogen. All antibodies were diluted with BOND™ primary antibody diluent (cat#AR9352, Leica). IHC-stained slides were mounted in Surgipath Micromount mounting medium (cat#38017322, Leica).

Three mHNcSCC tissue samples from the original cohort of 15 patients underwent immunofluorescence (IF) staining to determine co-expression of proteins. VectaFluor Excel antimouse 488 (ready-to-use; cat#VEDK2488, Vector Laboratories, Burlingame, CA, USA) and Alexa Fluor anti-rabbit 594 (1:500; cat#A21207, Life Technologies, Carlsbad, CA, USA) were used to determine marker expression. All IF-stained slides were mounted in Vecta Shield Hardset mounting medium with 4',6-diamidino-2-phenylindole (Vector Laboratories). All antibodies were diluted in BOND™ primary diluent (Leica). All IHC and IF staining was performed on the Leica BOND RX™ auto-stainer (Leica, Nussloch, Germany).

Human tissues used for positive controls were seminoma for OCT4 and NANOG, skin for SOX2, breast carcinoma for KLF4, and colon for c-MYC. To determine the specificity of the amplification cascade used in IHC staining, negative controls were performed on sections of mHNcSCC tissue samples using a matched isotype control for both mouse (ready-to-use; cat#DK2488, Dako, Glostrup, Denmark) and rabbit (ready-to-use; cat#DK1594, Dako) primary antibodies, and a combination of both was used for determining specificity of the amplification cascade used in IF staining.

**In-situ Hybridization**

Four micro meter-thick FFPE sections of six mHNcSCC tissue samples from the original cohort of 15 patients, underwent ISH on the Leica BOND RX™ auto-stainer with probes for OCT4 (NM_002701.4) and SOX2 (NR_075091.1), NANOG (NM_024865.2), KLF4 (NM_00134052), and c-MYC (NM_002467.4). All probes used for ISH were obtained from Advanced Cell Diagnostics (Newark, CA, USA). Probes were detected using the RNAscope 2.5 LS Reagent Brown Kit (cat#322100, Advanced Cell Diagnostics).

Human tissues used for positive controls were seminoma for OCT4 and NANOG, skin for SOX2, breast carcinoma for KLF4, and colon for c-MYC. Negative controls were demonstrated on sections of mHNcSCC tissue samples using a probe for DapB (EF191515) (cat#312038, Advanced Cell Diagnostics).

**Reverse-Transcription Quantitative Polymerase Chain Reaction**

Total RNA was isolated from four snap-frozen mHNcSCC tissue samples (20 mg/sample) and three mHNcSCC-derived primary cell lines (5 × 10⁵ viable cells/sample) from the original cohort of 15 patients. Tissues were homogenized using the Omni Tissue Homogenizer (Omni TH, Omni International, Kennesaw, GA, USA) before preparation using the RNeasy Mini Kit (cat#74104, Qiagen). Frozen cell pellets were prepared using the RNeasy Micro Kit (cat#74004, Qiagen). A DNase digest step was included for both methods (cat#79254, Qiagen). Quantitation of the RNA was determined using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific). Transcript expression was determined using the Rotor-Gene Q (Qiagen) and the Rotor-Gene Multiplex RT-qPCR Kit (cat#204974, Qiagen). The TaqMan probe primers were used for OCT4 (Hs03005111_g1), SOX2 (Hs01053049_s1), NANOG (Hs02387400_g1), KLF4 (Hs00358836_m1), and c-MYC (Hs00153408_m1; cat#4331182). The level of gene expression was normalized to that of the housekeepers GAPDH (Hs99999905_m1) and PUM1 (Hs00206469_m1; cat#4331182), all from Thermo Fisher Scientific. Universal human reference...
RNA (UHR; cat#636690, Clontech Laboratories, Mountain View, CA, USA) – total RNA from a range of normal adult human tissues, was used as a calibrator for the 2^{ΔΔCt} analysis. NTERA-2 cells were included as a positive control, and a no template control (NTC) included to control for contamination. End-point amplification products were checked for the presence of bands of the correct size by gel electrophoresis on 2% agarose gels (cat#G402002, Thermo Fisher Scientific). Graphs were generated using GraphPad Prism (v8.0.2, San Diego, CA, USA) and results presented as expression fold change relative to UHR.

Western Blotting
Total protein extracts from three mHNcSCC-derived primary cell lines were resolved by one-dimensional polyacrylamide gel electrophoresis (Bio-Rad, Hercules, CA, USA) on 4–12% Bis-Tris gels using 20 µg total protein/sample and transferred to polyvinylidene difluoride membranes (Bio-Rad). The membranes were blocked in 1X iBind™ Flex FD Solution (Thermo Fisher Scientific), and then probed with the primary antibodies for c-MYC (1:1,000; cat#Ab32072, Abcam), KLF4 (1:1,000; cat#NBP2-24749, Novus Biologicals), NANOG (1:1,000; cat#Ab109250, Abcam), OCT4 (1:500; cat#ab109183, Abcam), SOX2 (1:500; cat#48-1400, Thermo Fisher Scientific), and α-tubulin (1:1,000; cat#62204, Thermo Fisher Scientific). They were then incubated with the appropriate secondary antibody, goat anti-rabbit horseradish peroxidase (HRP) conjugate (1:1,000; cat#ab6721, Thermo Fisher Scientific), for the five iPSC markers and goat anti-mouse—Alexa 488 (1:1,000; cat#A21202, Thermo Fisher Scientific) for the loading control (α-tubulin). HRP-conjugated secondary antibody detection was achieved using Clarity Western enhanced chemiluminescence substrate (Bio-Rad) and a ChemiDoc MP imaging system (Bio-Rad).

FIGURE 1 | Representative hematoxylin and eosin (A) and immunohistochemical (B–F) stained slides of metastatic head and neck cutaneous squamous cell carcinoma (mHNcSCC) tissue samples, demonstrating the tumor nests (TNs, arrows) separated by peritumoral stroma (PTS, arrowheads) (A), and nuclear and cytoplasmic expression of OCT4 (B, brown) by cells within the PTS (arrowheads), and cytoplasmic expression in occasional cells within the TNs (arrows). NANOG (C, brown) was expressed on the cytoplasm of cells within the TNs (arrows). Cells within the PTS did not express for NANOG (arrowheads). SOX2 (D, brown) was expressed on the nucleus and the cytoplasm of cells within the TNs (arrows) and the PTS (arrowheads). KLF4 (E, brown) was present on the cytoplasm in cells throughout the TNs (arrow), and to a lesser extent, on cells within the PTS (arrowheads). c-MYC (F, brown) showed cytoplasmic and occasional nuclear expression on cells within the TNs (arrows) and cytoplasmic and nuclear expression in cells within the PTS (arrowheads). Nuclei were counter-stained with hematoxylin. Original magnification: 400x.
In vitro Tumorsphere Formation Assays

Tumorsphere suspension cultures were developed using three mHNcSCC-derived primary cell lines. Briefly, 2.5 × 10^5 live cells from adherent cultures at passages 7–9 were seeded in 24 mL StemXVivo serum-free tumorsphere media (cat#CCM012, R&D Systems, Minneapolis, MN, USA), in T75 NunclonTM SpheraTM EasYFlasks (cat#174952, Thermo Fisher Scientific) supplemented as per the manufacturer’s protocol. Cells were maintained in a 5% incubator at 37°C for up to 10 days, and fed every 3–4 days with the addition of 12 mL of media. Cultures were observed, photographed and measured daily from day 3 post seeding under an Olympus CKX53 Microscope (Tokyo, Japan). Three fields of view were captured for each cell line. From each field of view five representative spheres were identified and two measurements per sphere were performed to establish an average size within each. Culture results are reported as the average size of all spheres measured and the percentage of spheres measured that exceed the 50 µm threshold, which is the minimum required size for a sphere to be considered positive (45).

Statistical Analysis

Because cell counting was performed for each mHNcSCC tissue sample that underwent IHC staining and ISH staining was tested for all five iPSC markers, and because three technical replicates were done for each marker, a repeated measures analysis was performed to test for differences between markers using Generalized Estimating Equations (GEE) (46). The marginal means and their standard errors were estimated from the GEE model and compared between markers using sequential Bonferroni correction for multiple comparisons. A p-value of < 0.05 was taken as significant.

RESULTS

IHC Staining Showed Expression of iPSC Markers OCT4, NANOG, SOX2, KLF4, and c-MYC in mHNcSCC Tissue Samples

The diagnosis of mHNcSCC was confirmed in all 15 tissue samples showing TNs (arrows) surrounded by the PTS (arrowheads) (Figure 1A). All 15 mHNcSCC tissue samples exhibited nuclear expression of OCT4 (Figure 1B) by cells within the PTS and faint cytoplasmic staining in occasional cells within the TNs. NANOG (Figure 1C) was expressed in the cytoplasm of cells within the TNs, but not the cells within the PTS. SOX2 (Figure 1D) was expressed on the nucleus and cytoplasm of cells within the TNs, and in the nucleus of cells within the PTS. KLF4 was present in the cytoplasm of cells throughout the TNs (Figure 1E), and to a lesser extent, cells within the PTS (Figure 1E). Cytoplasmic and nuclear expression of c-MYC (Figure 1F) was observed in cells within the TNs and occasional cells within the PTS. Figure insets have been provided to show enlarged views of the corresponding images.

Human tissues for positive controls showed the expected staining patterns: for OCT4 (Supplementary Figure 1A) and NANOG (Supplementary Figure 1B) on seminoma, SOX2 (Supplementary Figure 1C) on skin, KLF4 (Supplementary Figure 1D) on breast carcinoma, and c-MYC (Supplementary Figure 1E) on colon. Specificity of the secondary antibodies was confirmed on sections of mHNcSCC tissue samples using a matched isotype control for both mouse and rabbit primary antibodies (Supplementary Figure 1F).

Statistical analyses of cell counting results for immunohistochemically-stained slides of metastatic head and neck cutaneous squamous cell carcinoma demonstrating a statistically significant difference between the mean percentage of cells stained positively in both the TN and the PTS for each induced pluripotent stem cell (iPSC) marker (p < 0.0005). Error bars: 95% confidence interval. ***p < 0.005.

IF Staining Showed Three CSC Subpopulations Within mHNcSCC Tissue Samples

IF staining demonstrated abundant expression of c-MYC (Figures 3A–C, green) on the cells within the PTS (arrowheads) and the TNs (arrows). The c-MYC+ subpopulations within the TNs and the PTS also demonstrated cytoplasmic expression of KLF4 (Figure 3A, red). Most of the c-MYC+ cells within...
the TNs and few c-MYC+ within the PTS also expressed NANOG (Figure 3B, red) with few c-MYC+ cells within the PTS not expressing NANOG (Figure 3B). These c-MYC+ subpopulations within the TNs and the PTS exhibited nuclear and cytoplasmic expression of SOX2 (Figure 3C, red). The KLF4+ (Figure 3D, red) cells within the TNs and the PTS also expressed OCT4 (Figure 3D, green). The majority of these OCT4+ (Figures 3E,F, green) cells within the TNs and the PTS also expressed NANOG (Figure 3E, red), and all of them expressed SOX2 (Figure 3F, red). Figure insets have been provided to show enlarged views of the corresponding images.

Taken altogether, there is an OCT4+/NANOG+/SOX2+/KLF4+/c-MYC+ CSC subpopulation and an OCT4+/NANOG-/SOX2+/KLF4+/c-MYC+ subpopulation within the TNs, and an OCT4+/NANOG+/SOX2+/KLF4+/c-MYC+ subpopulation within the PTS of mHNcSCC.

Images of individual stains of the merged images presented in Figure 3 are provided in Supplementary Figure 2. Specificity of secondary antibodies was confirmed on the negative control (Supplementary Figure 2M), which demonstrated minimal staining.

**ISH Demonstrated mRNA Transcripts of iPSC Markers in mHNcSCC Tissue Samples**

ISH showed mRNA expression of OCT4 (Figure 4A), NANOG (Figure 4B), SOX2 (Figure 4C), KLF4 (Figure 4D), and c-MYC (Figure 4E) throughout the TNs (arrows), and to a lesser extent, the PTS (arrowheads), in all six mHNcSCC samples examined.

Human tissues used for positive controls demonstrated positive staining of OCT4 (Supplementary Figure 3A) and NANOG (Supplementary Figure 3B) on sections of seminoma, SOX2 (Supplementary Figure 3C) on skin, KLF4 (Supplementary Figure 3D) on breast carcinoma, and c-MYC (Supplementary Figure 3E) on colon. The negative control (Supplementary Figure 3F) on sections of mHNcSCC tissue samples confirmed the specificity of the primary antibodies.

Statistical analyses of the cell counting results for the ISH-stained slides demonstrated a statistically significant difference between the mean proportion of cells that stained positively for each iPSC marker (p < 0.0005) (Figure 5). c-MYC (0.70, 95%CI 0.67–0.73) had highest mean proportion of positive cells, followed by KLF4 (0.68, 95%CI 0.66–0.71) although there was no statistically significant difference between them. OCT4 (0.54, 95%CI 0.49–0.59) and NANOG (0.48, 95%CI 0.47–0.50) had significantly lower mean proportions of positive cells compared with c-MYC and KLF4, but were not significantly different from each other (p < 0.0005) (Figure 5). The mean proportion of cells that stained positively for SOX2 was significantly lower than the other four iPSC markers (0.31, 95%CI 0.26–0.36) (p < 0.0005) (Figure 5).

**RT-qPCR Demonstrated mRNA Transcripts of iPSC Markers in mHNcSCC Tissue Samples and mHNcSCC-Derived Primary Cell Lines**

RT-qPCR analysis demonstrated transcript expression of OCT4, NANOG, SOX2, KLF4, and c-MYC in all four mHNcSCC tissue samples (Figure 6A) and in all three of the mHNcSCC-derived primary cell lines (Figure 6B).

In the mHNcSCC tissue samples c-MYC showed a biologically significant increase in expression, relative to UHR. SOX2 had a biologically significant (increase in expression, relative to UHR. SOX2 had a biologically significant decrease in expression,
FIGURE 4 | Representative in situ hybridization images of a metastatic head and neck cutaneous squamous cell carcinoma tissue sample demonstrating expression of mRNA transcripts of induced pluripotent stem cell markers. Transcripts for OCT4 (A, brown), NANOG (B, brown), SOX2 (C, brown), KLF4 (D, brown) and c-MYC (E, brown) were present throughout the TNs (arrows), and to a lesser degree, in the PTS (arrowheads). Nuclei were counter-stained with hematoxylin (A–E, blue). Original magnification: 1000x.

relative to UHR. The markers with the highest to the lowest mRNA expression were: c-MYC > OCT4, KLF4 ≥ NANOG ≥ SOX2. In the mHNcSCC-derived primary cell lines, OCT4, NANOG, and SOX2 all showed a biologically relevant decrease in expression, relative to UHR. The markers with the highest to the lowest mRNA expression were: c-MYC > KLF4 > OCT4 > NANOG ≥ SOX2.

Specific amplification of the products was demonstrated by electrophoresis of qPCR products on 2% agarose gels (Supplementary Figure 4). The expected size amplicons were observed, and no products were observed in the NTC reactions (Supplementary Figure 4).

Western Blotting Demonstrated Expression of SOX2, KLF4, and c-MYC but Not OCT4 and NANOG by mHNcSCC-Derived Primary Cell Lines

WB of mHNcSCC-derived primary cell lines derived from mHNcSCC tissue samples from three of the original cohort of 15 patients showed very low expression levels of SOX2 over two bands: one at the expected 35 kDa size and another at 40–42 kDa (Figure 7A), which is consistent with one of its known post-translational modifications (47). KLF4 (Figure 7B) and c-MYC (seen as two bands) (Figure 7C) were expressed in all three mHNcSCC-derived primary cell lines; the lower band for c-MYC may be MYC-nick (48). NANOG (Figure 7D) and OCT4 (Figure 7E) were below detectable levels. Equal amounts of proteins were loaded into each lane, as confirmed by α-tubulin staining (Figure 7F).

mHNcSCC-Derived Primary Cell Lines Demonstrated Tumorsphere Formation in vitro

All three mHNcSCC-derived primary cell lines demonstrated in vitro tumorsphere formation (Figures 8A–C) at the first passage with a mean diameter at cessation of culture averaging 62.6, 72.9, and 88.7 µm respectively (Supplementary Figure 5), meeting our threshold (spheres that were > 50 µm in size).
The percentage of spheres measured that exceeded the 50 µm threshold in these cell lines were 93.3, 100, and 100%, respectively (45). Tumorsphere culture was halted at the first signs of the on-set of dark centers indicating cell death. This occurred on days 6, 7, and 5 respectively. This provides some preliminary evidence of stem cell functionality within the mHNcSCC-derived primary cell lines.

**DISCUSSION**

NMSCs are the commonest cancers diagnosed worldwide (49) and make up one third of all malignancies (50), with 20% being SCC (51).

Tumor initiation (23), development (52), recurrence (53), and chemoradiation resistance have been attributed to the presence of CSCs (54), which have been recently identified within primary HNcSCC (19) using the five iPSC markers used in this study. Targeting CSCs has been suggested as a novel treatment approach for cancer (55).

In this study, we identified three CSC subpopulations within mHNcSCC: an OCT4+/NANOG+/SOX2+/KLF4+/c-MYC- subpopulation and an OCT4+/NANOG-/SOX2+/KLF4+/c-MYC+ subpopulation within the TNs, and an OCT4+/NANOG+/SOX2+/KLF4+/c-MYC+ subpopulation within the PTS.

We have previously identified an OCT4+/NANOG+/SOX2+/KLF4+/c-MYC+ CSC subpopulation within the TNs, and an OCT4+/NANOG+/SOX2+/KLF4+/c-MYC- and an OCT4+/NANOG-/SOX2+/KLF4+/c-MYC+ CSC subpopulation within the PTS of primary HNcSCC (19). The CSC subpopulations within primary HNcSCC differ from the CSC subpopulations identified in mHNcSCC demonstrated in this study. We have identified an OCT4+/NANOG-/SOX2+/KLF4+/c-MYC+ population within the TNs in mHNcSCC, which is not present in primary HNcSCC. The OCT4+/NANOG-/SOX2+/KLF4+/c-MYC+ CSC
subpopulation identified within the PTS in primary HNcSCC, is not demonstrated in mHNcSCC in this study. Using the same iPSC markers, we have also shown the presence of two CSC subpopulations within head and neck metastatic malignant melanoma (HNmMM): an OCT4+/SOX2+/KLF4+/c-MYC+CSC subpopulation within the TNs, and another in the PTS with NANOG present only in two of the 20 cases studied (44). Three out of four primary cell lines derived from four different HNmMM tissue samples formed tumorspheres in vitro. As with the current study of mHNcSCC, the formation of tumorspheres in HNmMM-derived primary cell lines in vitro, provides preliminary functional evidence of the presence of CSCs in HNmMM tissues (44).

The presence of the CSC subpopulation within the PTS of mHNcSCC was supported by both protein and mRNA expression of OCT4, NANOG, SOX2, KLF4, and c-MYC on the cells within the PTS by IHC staining and ISH, respectively. The absence of NANOG in one of the two CSC subpopulations within the TNs aligns with previous studies demonstrating dispensability of NANOG in the presence of the other four iPSC markers for induction of pluripotency (13), the phenotype exhibited by CSCs (8). As with primary HNcSCC (19), IHC staining in this study demonstrated localization of NANOG to CSCs in the TNs, and ISH detected mRNA transcripts for NANOG in cells within the TNs and, to a lesser extent, those within the PTS. The presence of NANOG mRNA in cells within the TNs and the absence of its protein in one of the two CSC subpopulations within the TNs, is consistent with the dispensability of NANOG for pluripotent capability (14). The absence of NANOG in the aforementioned CSC subpopulation is interesting, as NANOG has been associated with the development of cervical SCC when it is present on stromal cells (56). NANOG has been used as a CSC marker in many cancer types (16, 37–40, 57). Targeting NANOG in head and neck squamous cell carcinoma-derived spheroid cells significantly inhibits tumor aggressiveness and increases chemosensitivity to cisplatin (57); perhaps targeting NANOG within mHNcSCC would have a similar effect on these parameters.
The presence of CSCs within mHNcSCC tissue samples is supported by RT-qPCR which demonstrated the presence of all five iPSC markers in three mHNcSCC-derived primary cell lines, while WB showed expression of these markers except for NANOG and OCT4. The capability of the three mHNcSCC-derived primary cell lines to form initial tumorspheres in vitro provides preliminary evidence of the presence of CSCs within mHNcSCC. Further functional tests to confirm these findings, such as additional passages and in vivo xenotransplantation of the said tumorspheres into mice, should be undertaken.

As with our previous study of primary HNcSCC (19), SOX2 expression was observed within mHNcSCC tissue samples and mHNcSCC-derived primary cell lines, albeit at very low levels. This may suggest the dispensability of SOX2 following metastasis, as observed in metastatic malignant melanoma (58).

If SOX2 is dispensable following metastasis in mHNcSCC as in metastatic malignant melanoma (58), a correlation between low SOX2 expression levels and a more aggressive cancer may be expected. However, Li et al. (59) demonstrate that SOX2 is a downstream target of the Hippo effector TAZ in HNcSCC, which is capable of reprogramming differentiated cancer cells into CSCs, and that SOX2 and TAZ upregulation are both associated with poorer overall survival in HNcSCC. Given the presence of SOX2 in mHNcSCC (60) and its association with local recurrence and metastasis, we speculate the TAZ-SOX2 axis as an important determinant of CSC stemness in this tumor. The low expression of SOX2 within mHNcSCC-derived primary cell lines and the lower proportions of SOX2 positive cells in mHNcSCC tissue samples on IHC staining and ISH staining compared to the other four iPSC markers may reflect the aggressiveness of this cancer, as decreased SOX2 expression has been associated with carcinogenesis and the development of OCSCC (60).

RT-qPCR and WB analyses showed some differences of the expression profile in the iPSC markers between the mHNcSCC tissue samples and mHNcSCC-derived primary cell lines. It has been observed that the expression of up to 10% of genes is altered within five passages during tumorsphere formation in vitro (61). These alterations in gene expression driven by the cell culture environment may explain why SOX2 was expressed at a very low level, and why OCT4 and NANOG were not detected by WB in mHNcSCC-derived primary cell lines, compared with the RT-qPCR results for the mHNcSCC tissue samples. It may also account for the differences in the RT-qPCR results between the mHNcSCC tissue samples and the mHNcSCC-derived primary cell lines.

Given its role and overexpression in cSCC (62), it was unsurprising that KLF4 was expressed in all mHNcSCC tissue samples and mHNcSCC-derived primary cell lines. Our finding of c-MYC expression in mHNcSCC aligns with reports of c-MYC overexpression in other types of carcinoma (29, 37, 39, 40).

The finding of OCT4 expression in mHNcSCC is consistent with our previous study demonstrating OCT4 expression in primary HNcSCC (19) and other solid tumors (63). As a key regulator of pluripotency in the early mammalian embryo and given it is consistently expressed by ESCs and hematopoietic and neural stem cells (26), the presence of OCT4 in mHNcSCC supports the presence of primitive CSC subpopulations in this tumor.

Expression of components of the renin-angiotensin system (RAS) by CSCs has been demonstrated in different cancer types including glioblastoma (64), OCSCC affecting the oral tongue (65), buccal mucosa (66), and lip (67) squamous cell carcinoma (SCC), primary HNcSCC (68), metastatic colon adenocarcinoma (42), and metastatic malignant melanoma (43). This suggests CSCs in these tumors may be targeted by modulation of the RAS (12, 55).

We have demonstrated the presence of three putative CSC subpopulations within mHNcSCC. Further, investigating the expression of the RAS—important regulator of stem cells (69, 70)—by these CSC subpopulations may provide an avenue of therapeutic targeting of them in the treatment of this aggressive cancer (55). These findings are novel, and further investigation with a larger sample size with functional studies are needed to confirm the CSC subpopulations identified in this study.

**CONCLUSIONS**

This study demonstrates expression of the iPSC markers OCT4, NANOG, SOX2, KLF4, and c-MYC in mHNcSCC, with the presence of three CSC subpopulations. mHNcSCC-derived primary cell lines express transcripts of OCT4, NANOG, SOX2, KLF4 and c-MYC. SOX2, KLF4, and c-MYC, but not OCT4 and NANOG proteins. These cell lines form tumorspheres in vitro, at a single passage. The identification of CSCs within mHNcSCC may open novel avenues for therapeutic targeting of this aggressive cancer.
REFERENCES

1. Brougham NDL, Tan ST. The incidence and risk factors of metastasis for cutaneous squamous cell carcinoma—implications on the T-classification system. J Surg Oncol. (2014) 110:876–82. doi: 10.1002/jso.23731

2. Ch’ng S, Maitra A, Allison R, Chaplin J, Gregor RT, Lea R, et al. Parotid and cervical nodal status predict prognosis for patients with head & neck metastatic cutaneous squamous cell carcinoma - a multicentre study of the New Zealand population. J Surg Oncol. (2008) 98:101–5. doi: 10.1002/jso.21092

3. Rudolph R, Zelac DE. Squamous cell carcinoma of the skin. Plast Reconstr Surg. (2004) 114:82e–94e. doi: 10.1097/PRS.0000138243.45735.8A

4. Brougham NDL, Dennett ER, Cameron R, Tan ST. Incidence and risk factors of metastasis for cutaneous squamous cell carcinoma. J Surg Oncol. (2012) 106:811–5. doi: 10.1002/jso.23155

5. Brougham NDL, Dennett ER, Tan ST. Changing incidence of non-melanoma skin cancer in New Zealand. ANZ J Surg. (2011) 81:633–6. doi: 10.1111/j.1445-2197.2010.05583.x

6. Ch'ng S, Maitra A, Lea R, Brasch H, Tan ST. Parotid metastasis - an independent prognostic factor for head and neck cutaneous squamous cell carcinoma. J Plast Reconstr Aesth Surg. (2006) 59:1288–93. doi: 10.1016/j.bjps.2006.03.043

7. Xu R, Cai MY, Luo RZ, Tian X, Chen MK. The expression status and prognostic value of cancer stem cell biomarker CD133 in cutaneous squamous cell carcinoma. JAMA Dermatol. (2016) 152:305–11. doi: 10.1001/jamadermatol.2015.3781

8. Battie E, Clevers H. Cancer stem cells revisited. Nat Med. (2017) 23:1124–34. doi: 10.1038/nm.4409

9. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. (2006) 355:1253–61. doi: 10.1056/NEJMr061808

10. Clement V, Sanchez P, De Trablo N, Radovanovic I, Altaba AR. HEDGEHOG-GLI1 signaling regulates human gliaoma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. (2007) 17:165–72. doi: 10.1016/j.cub.2006.11.033

11. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. (2009) 15:1010–2. doi: 10.1038/nm0909-1010

12. Munro MJ, Wickremesekera AC, Davis PF, Marsh R, Tan ST, Itinteang T. Renin-angiotensin system and cancer: a review. Int J Cancer Sci. (2017) 4:1–6. doi: 10.15761/ICST.1000231

13. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. (2006) 126:663–76. doi: 10.1016/j.cell.2006.07.024

14. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. (2007) 318:1917–20. doi: 10.1126/science.1151526

15. Humphries HN, Wickremesekera SK, Marsh RW, Brasch HD, Mehrotra S, Tan ST, et al. Characterization of cancer stem cells in colon adenocarcinoma metastasis to the liver. Front Surg. (2018) 22:76. doi: 10.3389/fsurg.2017.00076

16. Cane R, Kennedy-Smith A, Brasch HD, Savage S, Marsh RW, Tan ST, et al. Characterization of cancer stem cells in renal clear cell carcinoma. Stem Cell Regen Biol. (2019) 4:6–16. doi: 10.15432/4761-0589.19.2462

17. Munro MJ, Wickremesekera SK, Peng L, Marsh RW, Itinteang T, Tan ST. Cancer stem cell subpopulations in primary colon adenocarcinoma. PLoS ONE. (2019) 14:e0221963. doi: 10.1371/journal.pone.0221963

18. Koh SP, Brasch HD, de Jongh J, Itinteang T, Tan ST. Cancer stem cell subpopulations in moderately differentiated head and neck cutaneous squamous cell carcinoma. Heliyon. (2019) 5:e022257. doi: 10.1016/j.heliyon.2019.e022257

19. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. (2003) 17:126–40. doi: 10.1101/gad.224503

20. Siegle JM, Basin A, Sastre-Perona A, Yonekubo Y, Brown J, Sennett R, et al. SOX2 is a cancer-specific regulator of tumour initiating potential in cutaneous squamous cell carcinoma. Nat Commun. (2014) 5:4511. doi: 10.1038/ncomms5511

21. Lien WH, Guo X, Polak L, Lawton LN, Young RA, Zheng D, et al. Genome-wide maps of histone modifications unwind in vivo chromatin states of the hair follicle lineage. Cell Stem Cell. (2011) 9:219–32. doi: 10.1016/j.stem.2011.07.015
23. Boumahl S, Driedens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, et al. SOX2 controls tumour initiation and cancer stem cell functions in squamous-cell carcinoma. *Nature*. (2014) 511:246–50. doi: 10.1038/nature13305

24. Cauffman G, Van de Velde H, Liebaers I, Van Steirteghem A. Oct-4 mRNA and protein expression during human preimplantation development. *Mol Hum Reprod*. (2004) 11:173–81. doi: 10.1093/molhr/gah155

25. Ding J, Xu H, Faiola F, Ma’ayan A, Wang J. Oct4 links multiple epigenetic pathways to the pluripotency network. *Cell Res*. (2012) 22:155–67. doi: 10.1038/cr.2011.179

26. Koo BS, Lee SH, Kim JM, Huang S, Kim SH, Rho YS, et al. Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. *Oncogene*. (2015) 34:2317–24. doi: 10.1038/onc.2014.174

27. Chit P, Lee CC, Huang CY, Lin SC, Liu CJ, Tsai TH, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. *Cancer Res*. (2008) 68:4085–95. doi: 10.1158/0008-5472.CCR-07-0432

28. Chambers I, Silva J, Colby D, Nichols I, Nijmeijer B, Robertson M, et al. Nanog safeguards pluripotency and mediates germline development. *Nature*. (2007) 450:1230–4. doi: 10.1038/nature06403

29. Munro MJ, Wickremesekera SK, Peng L, Tan ST, Itinteang T. Cancer stem cells in colorectal cancer: a review. *J Clin Pathol*. (2018) 71:110–6. doi: 10.1136/jclinpath-2017-204739

30. Bourillot PY, Savatier P. Krüppel-like transcription factors and control of cell differentiation. *Opin Cell Biol*. (2016) 41:225–33. doi: 10.1016/j.opicb.2015.10.009

31. Laurenti E, Wilson A, Trumpp A. Myc’s other life: stem cells and beyond. *Nature*. (2010) 465:222–30. doi: 10.1038/nature09095

32. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. *Graefe’s Arch Clin Exp Ophthalmol*. (1992) 230:1–11. doi: 10.1007/BF01613947

33. Royds JA, Sharrard RM, Parsons MA, Lawry J, Rees R, Cottam D, et al. c-MYC oncogene expression in ocular melanomas. *Cancer Res*. (2008) 68:4096–97. doi: 10.1158/0008-5472.CAN-07-3595

34. Yoganandarajah V, Patel J, van Schaijk B, Bockett N, Brasch HD, Paterson E, et al. Identification of cancer stem cell subpopulations in head and neck metastatic malignant melanoma. *Cells*. (2020) 9:e324. doi: 10.3390/cells9020324

35. Lee CH, Yu CC, Wang BY, Chang WW. Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. *Oncotarget*. (2016) 7:12151–26. doi: 10.18632/oncotarget.6261

36. Hanley JA, Negassa A, Edwards MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. *Am J Epidemiol*. (2003) 157:364–75. doi: 10.1093/aje/kwf215

37. Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. *Med J Aust*. (2006) 184:6–10. doi: 10.5694/j.1326-5377.2006.tb00086.x

38. Surdu S. Non-melanoma skin cancer: occupational risk from UV light and arsenic exposure. *Rev Environ Health*. (2014) 29:253–65. doi: 10.1515/reveh-2014-0040

39. Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. *Am J Clin Dermatol*. (2017) 18:17–24. doi: 10.1007/s40257-016-0207-3

40. Cabrera MC, Hollingsworth RE, Hurt EM. Cancer stem cell plasticity and tumor hierarchy. *World J Stem Cells*. (2015) 7:27–36. doi: 10.4252/wjssc.v7.i1.27

41. Petzsch C, Tyutunnuykova A, Pantel K, Dubrovskas A. Cancer stem cells: the root of tumor recurrence and metastases. *Semin Cancer Biol*. (2017) 44:10–24. doi: 10.1016/j.semcancer.2017.02.011

42. Ishii H, Iwatsuki M, Ieta K, Ohta D, Haraguchi N, Mimiori K, et al. Cancer stem cells and chemoradiation resistance. *Cancer Sci*. (2008) 99:1871–7. doi: 10.1111/j.1349-7006.2008.00914.x

43. Roth I, Wickremesekera SK, Davis PJ, Tan ST. Therapeutic targeting of cancer stem cells via modulation of the renin-angiotensin system. *Front Oncol*. (2019) 9:745. doi: 10.3389/fonc.2019.00745

44. Gu TT, Liu SY, Zheng PS. Cytoplasmic NANOG-positive stromal cells promote human cervical cancer progression. *Am J Pathol*. (2012) 181:652–61. doi: 10.1016/j.ajpath.2012.04.008

45. Huang CE, Yu CC, Hu FW, Chou MY, Tsai IL. Enhanced chemosensitivity by targeting Nanog in head and neck squamous cell carcinomas. *Int J Mol Sci*. (2014) 15:4935–48. doi: 10.3390/ijms15091495

46. Schaefer S, Segalada C, Cheng PF, Bonalli M, Parfejevs V, Levesque MP, et al. Sox2 is dispensable for primary melanoma and metastasis formation. *Oncogene*. (2017) 36:4516–24. doi: 10.1038/onc.2017.55

47. Li J, Li Z, Wu Y, Wang Y, Wang D, Zhang W, et al. The Hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma. *Cell Death Dis*. (2019) 10:1–15. doi: 10.1038/s41419-018-1383-0

48. Naini FB, Shabik PA, Abdollahi A, Hodjat M, Mohammadpour H, Khoozestani NK. Relative expression of OCT4, SOX2 and NANOG in oral squamous cell carcinoma versus adjacent non-tumor tissue. *Arthritis Res Ther*. (2010) 12:R83. doi: 10.1186/ar3010

49. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey, et al. Induction of KLF4 in basal keratinocytes blocks the proliferation–differentiation switch and initiates squamous epithelial dysplasia. *Oncogene*. (2005) 24:1491–500. doi: 10.1038/sj.onc.1208307

50. Villodre ES, Kipper FC, Pereira MB, Lenz G. Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis. *Cancer Treat Rev*. (2016) 51:1–9. doi: 10.1016/j.ctrv.2016.10.003

51. Bradshaw AR, Wickremesekera AC, Brasch HD, Chibnall AM, Davis PF, et al. Globlomata multiforme cancer stem cells express components of the renin–angiotensin system. *Front Surg*. (2016) 3:51. doi: 10.3389/fsurg.2016.00051
65. Itinteang T, Dunne JC, Chibnall AM, Brasch HD, Davis PF, Tan ST. Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma express components of the renin-angiotensin system. *J Clin Pathol.* (2016) 69:942–5. doi: 10.1136/jclinpath-2016-203736

66. Featherston T, Yu HH, Dunne JC, Chibnall AM, Brasch HD, Davis PF, et al. Cancer stem cells in moderately differentiated buccal mucosal squamous cell carcinoma express components of the renin-angiotensin system. *Front Surg.* (2016) 3:52. doi: 10.3389/fsurg.2016.00052

67. Ram RS, Brasch HD, Dunne JC, Davis PF, Tan ST, Itinteang T, et al. Cancer stem cells in moderately differentiated lip squamous cell carcinoma express components of the renin–angiotensin system. *Front Surg.* (2017) 4:30. doi: 10.3389/fsurg.2017.00030

68. Nallaiah S, Lee VMY, Brasch HD, de Jongh J, van Schaijik B, Marsh R, et al. Cancer stem cells within moderately differentiated head and neck cutaneous squamous cell carcinoma express components of the renin-angiotensin system. *J Plast Reconstr Aesthet Surg.* (2019) 72:1484–93. doi: 10.1016/j.bjps.2018.11.013

69. Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. *Hypertension.* (2006) 48:1095–102. doi: 10.1161/01.HYP.0000248211.82232.a7

70. Rodgers K, Xiong S, Steer R, DiZerega G. Effect of angiotensin II on hematopoietic progenitor cell proliferation. *Stem Cells.* (2000) 18:287–94. doi: 10.1634/stemcells.18-4-287

**Conflict of Interest:** TI, PD, and ST are inventors of the patents Cancer Diagnosis and Therapy (PCT/NZ2015/050108), Cancer Therapeutic (PCT/NZ2018/050006), Novel Pharmaceutical Compositions for Cancer Therapy (US/62/711709), and Cancer diagnosis and therapy (United States Patent No. 10281472). The authors of this manuscript have no external sources of funding to disclose.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Kilmister, Patel, van Schaijik, Bockett, Brasch, Paterson, Sim, Davis, Roth, Itinteang and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.